Scientists Discover How Cancer Cells Lose Their Identity and Find New Treatment Target
Researchers identified why some fat cancers become aggressive and found a potential new therapy approach using existing drugs.
Summary
Scientists studying liposarcoma, a type of fat cancer, discovered why some tumors become more aggressive and harder to treat. They found that aggressive cancer cells lose a key protein called PPARG2 that normally helps cells develop into healthy fat tissue. Without this protein, the cells get stuck in an immature state and can't differentiate properly. The researchers also discovered that these aggressive cancer cells become dependent on a growth factor called IGF1, making them vulnerable to targeted drugs that block IGF1 receptors. This finding could lead to more precise treatments for patients with this challenging cancer type.
Detailed Summary
This groundbreaking research reveals how certain cancer cells lose their cellular identity, offering new hope for treating aggressive sarcomas and potentially informing broader cancer treatment strategies.
Researchers at Dana-Farber Cancer Institute studied liposarcoma, a cancer affecting fat tissue that comes in two forms: well-differentiated (less aggressive) and dedifferentiated (highly aggressive). Using advanced single-cell sequencing technology, they analyzed normal fat tissue alongside both cancer types to understand what drives the aggressive transformation.
The team discovered that aggressive dedifferentiated liposarcoma cells lose a crucial protein called PPARG2, which normally guides cells to mature into healthy fat tissue. Without PPARG2, these cancer cells become trapped in an immature state, unable to complete normal development. They also found that these cells lose sensitivity to IGF1 signaling, a pathway important for cellular growth and metabolism.
Remarkably, when researchers restored PPARG2 expression in cancer cells, they could force the cells back toward normal fat cell development. This suggests that cellular differentiation programs, which decline with aging, play critical roles in cancer prevention. The loss of proper cellular identity may contribute to age-related cancer risk.
The research also revealed a therapeutic vulnerability: dedifferentiated liposarcoma cells overexpress IGF1 receptors, making them susceptible to IGF1-targeted antibody-drug conjugates. This finding could lead to more effective, less toxic treatments than traditional chemotherapy.
While this study focused on a rare cancer, the principles may apply broadly to understanding how aging affects cellular identity and cancer risk, potentially informing strategies for maintaining healthy cellular function throughout life.
Key Findings
- Aggressive liposarcoma cells lose PPARG2 protein, preventing normal fat cell development
- Restoring PPARG2 expression alone can force cancer cells back toward healthy differentiation
- Cancer cells become vulnerable to IGF1 receptor-targeted drugs due to pathway disruption
- Loss of cellular identity programs may contribute to age-related cancer development
Methodology
Researchers used single-nucleus multiome sequencing and spatial profiling to analyze human normal adipose tissue, well-differentiated liposarcoma, and dedifferentiated liposarcoma samples. The study included functional experiments restoring PPARG2 expression in cancer cells.
Study Limitations
This study focused on a rare cancer type, so broader applicability remains unclear. The research was conducted primarily in laboratory settings, and clinical trials would be needed to validate therapeutic approaches in patients.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.